Cronos GroupSTU:7CI -1.04%85 Days Payable is 38.12 as of Mar. 2026, which is 44% below its 10-year median of 67.69. GuruFocus rates STU:7CI with a GF Score™ of 85/100 and a GF Value™ of €3.09 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 919 Drug Manufacturers companies, Cronos Group ranks worse than 80.63% on this metric.
The historical rank and industry rank for Cronos Group's Days Payable or its related term are showing as below:
STU:7CI'
s Days Payable Range Over the Past 10 Years
Min: 43.81 Med: 67.69 Max: 1209.98
Current: 43.81
During the past 12 years, Cronos Group's highest Days Payable was 1209.98. The lowest was 43.81. And the median was 67.69.
STU:7CI's Days Payable is ranked worse than 80.63% of 919
companies
in the Drug Manufacturers industry
Industry Median: 90.69
vs STU:7CI: 43.81
Cronos Group's Days Payable
declined
from Mar. 2025 (66.54) to Mar. 2026 (38.12).
It may suggest that Cronos Groupaccelerated paying its suppliers.
Cronos Group Days Payable Related Terms
Cronos Group Days Payable Historical Data
* Premium members only.
The historical data trend for Cronos Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Cronos Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cronos Group's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cronos Group (STU:7CI) has a Days Payable of 38.12 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cronos Group and its competitors. This is 44% below median its historical median of 67.69. Over the past decade, Cronos Group's Days Payable has ranged from 43.81 to 1,209.98. According to the industry distribution chart, Cronos Group ranks #741 out of 919 companies in the Drug Manufacturers industry, placing it in the top 80.6%.
Is Cronos Group's Days Payable too high?
Cronos Group's current Days Payable of 38.12 is 44% below median its 10-year median of 67.69. Over the past 10 years, this metric has ranged from a low of 43.81 to a high of 1,209.98. The Drug Manufacturers industry median Days Payable is 90.69. Cronos Group's value of 38.12 is 58% below this industry median. Based on the distribution chart, Cronos Group ranks #741 out of 919 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cronos Group has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #741 out of 919 companies for Days Payable. This places Cronos Group in the lower half of its industry. The industry median Days Payable is 90.69. Cronos Group's value of 38.12 is 58% below this benchmark. Historically, Cronos Group's own Days Payable has ranged from 43.81 to 1,209.98 over the past decade. While the company's 10-year median is 67.69 vs. the industry median of 90.69, Cronos Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.69, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current Days Payable of 38.12 is 58% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cronos Group and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current Days Payable is 38.12, which is 44% below median its own 10-year median of 67.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (STU:7CI) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.09, compared to a current price of €2.47 — trading 20.2% below its estimated fair value. The current Days Payable is 38.12, which is 44% below median its 10-year median of 67.69 and 58% below the Drug Manufacturers industry median of 90.69. Cronos Group's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cronos Group (STU:7CI), the current Days Payable is 38.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (STU:7CI) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of €2.47 is trading 20.2% below its estimated GF Value™ of €3.09.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for STU:7CI:
Days Payable: 38.12 (44% below median its 10-year median of 67.69)
GF Value™: €3.09 vs. price of €2.47 (20.2% below fair value)
Industry Position: 58% below the Drug Manufacturers median (#741 of 919)
No single metric tells the full story. See the STU:7CI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
85GF Score
Get the complete analysis for STU:7CI
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7CI has been successfully added to your 
